← All stocks

Sarepta Therapeutics, Inc.

SRPTPharmaceuticalsLatest filing used: 2026-11-05Filings on SEC EDGAR ↗

Strong balance sheet Fast grower

Fair value per share

No filings-based value

The filings alone are probably missing something here: the company's typical cash earnings in the filings are negative.

Last close

$16.07

Nov 13, 2026

How we decide

Ten years of results

Revenue

$2.2B in FY2025, up 16% on the year before

FY2016: $5MFY2017: $155MFY2018: $301MFY2019: $381MFY2020: $540MFY2021: $702MFY2022: $933MFY2023: $1.2BFY2024: $1.9BFY2025: $2.2B$1.2B$2.5BFY16FY19FY22FY25$2.2B
Show as table
YearRevenue
FY2016$5M
FY2017$155M
FY2018$301M
FY2019$381M
FY2020$540M
FY2021$702M
FY2022$933M
FY2023$1.2B
FY2024$1.9B
FY2025$2.2B

Cash earnings as a share of sales

-17.2% of sales in FY2025

FY2018: -120.6%FY2019: -117.5%FY2020: -121.9%FY2021: -45.6%FY2022: -46.0%FY2023: -26.1%FY2024: 9.8%FY2025: -17.2%-122%-56%10%FY16FY19FY22FY25-17%
Show as table
YearCash earnings as a share of sales
FY2016–
FY2017–
FY2018-120.6%
FY2019-117.5%
FY2020-121.9%
FY2021-45.6%
FY2022-46.0%
FY2023-26.1%
FY20249.8%
FY2025-17.2%

Shares outstanding

Share count rose 70% over 9 years

FY2017: 59MFY2018: 66MFY2019: 74MFY2020: 78MFY2021: 81MFY2022: 88MFY2023: 92MFY2024: 108MFY2025: 100M075M150MFY16FY19FY22FY25100.1M
Show as table
YearShares outstanding
FY2016–
FY201759M
FY201866M
FY201974M
FY202078M
FY202181M
FY202288M
FY202392M
FY2024108M
FY2025100M

No dividends paid in these years.

Delayed quote

Delayed price and chart from TradingView. This site does not receive or store these prices, and the fair value above does not use them. Showing the chart sends TradingView this page's address, the widget type, the ticker and your IP address, and TradingView may collect analytics; see Privacy.

Open on Yahoo Finance ↗

Sources. Company figures: SEC EDGAR (XBRL filings), latest filing used 2026-11-05. Interest rate: U.S. Treasury, 10-year par yield, 2026-11-13. Last close: IEX Historical Data, 2026-11-13.